FLT3 and acute myeloid leukemia: In a recently published phase I/II study of azacitidine in combination with second-generation FLT3 inhibitor, quizartinib, a small cohort of older/unfit patients with newly diagnosed FLT3 mutated AML had a CR/CRi rate of 87% and median OS of 19 months, suggesting combining a second-generation FLT3 inhibitor with azacitidine may improve outcomes [6].